Novartis stock slips amid Zolgensma safety concerns
FROM THE WIRE · SEEKINGALPHA.COM
Novartis (NVS) stock drops as the company faces fresh safety concerns over Zolgensma gene therapy after reports of tumors found in treated children. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishNew safety concerns over a flagship gene therapy can weigh on the shares of a large pharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis shares fall on fresh safety concerns over the Zolgensma gene therapy.
- 02Reports indicate tumors found in treated children.
- 03The text provides no further details on the financial impact.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets